Simplify Healthcare Is Positioned in the Leaders Category in the 2023 IDC MarketScape for U.S. Health Plan Product/Plan Benefit Configuration Solutions


Hitesh

Simplify Healthcare, a leading healthcare billing technology company, has announced that it has been ranked in the IDC MarketScape 2023 Leader category for Program Benefits/Product Configuration Solutions healthcare in the United States. The vendors in this study provide stand-alone product/package configuration solutions to payers and TPA organizations, whether they support […]

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research


Hitesh

Guardant Health, Inc., a leader in precision oncology, today announced an agreement with Illumina Inc., a global leader in DNA sequencing and chip-based technologies, helps resolve their ongoing litigation and drive joint resolution to foster long-term business partnerships. length of companies. The three-year agreement includes a joint request to dismiss […]

Astellas Completes Acquisition of Iveric Bio


Hitesh

Astellas Pharma Inc. announced that it has successfully completed the acquisition of IVERIC bio, Inc. with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has […]

Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities


Hitesh

Gilead Science Inc, announced its largest commitment to health equity for Indigenous Australian and Canadian communities. This initiative will support programs to remove social barriers to care that continue to contribute to HIV and viral hepatitis transmission in Indigenous communities. Gilead is in talks with two Indigenous-led organizations, the Lowitja […]

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)


Hitesh

Genmab A/S today announced that the European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP) has adopted a positive opinion proposing a conditional marketing authorization for ecoritamab as monotherapy in the treatment of adult patients with relapsed or refractory dual- or multiple-lineage systemic B-cell lymphoma (DLBCL). The European Commission’s […]